Critical mineral supply chain compliance
Critical mineral supply chain compliance is landing squarely on Healthcare & Life Sciences companies, driven by disclosure and sourcing obligations that touch medical device manufacturers, pharmaceutical producers, and diagnostics suppliers. The U.S. Food and Drug Administration has begun flagging mineral-dependent manufacturing inputs as supply continuity risks in device approval reviews, while the U.S. Federal Trade Commission has put sourcing claim accuracy under scrutiny and the European Chemicals Agency is enforcing traceability requirements under the Critical Raw Materials Act that directly affect EU-market product registrations. Compliance teams are now mapping tier-two and tier-three vendor contracts against these overlapping frameworks before they face their next regulatory submission cycle.
Watch
- EU Critical Raw Materials Act traceability rules: effective timelines for medical-grade inputs
- FDA device approval reviews increasingly flagging mineral-dependent Bill of Materials gaps
- FTC enforcement on 'responsibly sourced' mineral claims in health product marketing
- Dodd-Frank Section 1502 conflict mineral filings: scope creep into diagnostic device components
- APAC bilateral agreements restricting rare earth exports used in MRI and imaging equipment
Recent material activity in Healthcare & Life Sciences
Active monitoring in place across Healthcare & Life Sciences. Material developments related to critical mineral supply chain compliance will appear here as they are published.